Korio
Doylestown, US · Founded 2021 · Delaware corporation · 3 known investors
Korio is a clinical technology company offering a randomization and trial supply management (RTSM/IRT) platform for trial sponsors.
Also known as Korio, Inc.
Founders & leadership
Board
Investors · 3
Reported raises · per SEC filings
Form D private placements$12.3M disclosed across 2 of 3 rounds · 2023–2024
▶$5.5MraisedSep 2024 · 8 investors · Other TechnologyRule 506(b)
- Hugh R. RoomeDirector
- B. Bobby BahramDirector
- Ryan KeaneExecutive Officer, Director
- Chuck HarrisExecutive Officer, Director
- Austin PooleDirector
- Offering amount
- $5.5M
- Amount sold
- $5.5M
- First sale
- Aug 2024
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
▶$6.8MraisedOct 2023 · 39 investors · Other TechnologyRule 506(b)
- Chuck HarrisExecutive Officer, Director
- Ryan KeaneExecutive Officer, Director
- B. Bobby BahramDirector
- Hugh R. RoomeDirector
- Offering amount
- $6.8M
- Amount sold
- $6.8M
- First sale
- Sep 2023
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Company profile
researched Aug 2026Korio, Inc. is a Doylestown, Pennsylvania-based clinical trial technology company that develops a randomization and trial supply management (RTSM) platform, also referred to as interactive response technology (IRT). The platform is used by clinical trial sponsors to set up and run randomization and drug supply processes across study designs, and is paired with client services and support staff with RTSM domain expertise.
The company describes its approach as "compliance-centric": the IRT workflow is embedded into the software itself within a GxP framework, with the stated aim of making features reusable, processes repeatable and system quality consistent. Announced capabilities include reuse of client-level study settings across subsequent trials, creation and management of the IRT documentation suite inside the technology, real-time diagnostics on system availability, performance and health, adaptation to protocol changes, access to audit trail and cross-portfolio data, and flagging of integration disruptions.
Founding story
Korio was co-founded by Ryan Keane, who serves as CEO, and Chuck Harris, who serves as COO. The two bring a combined 30-plus years of experience in the IRT space, including ten years working together scaling an IRT start-up into a global provider. The founders stated they blended expertise from inside and outside the IRT industry when designing the platform.
Business model
Korio provides an RTSM/IRT software platform to life sciences customers, combined with expert client services and support teams that assist sponsors with trial setup and management.
Traction
The company reported a surge in customer adoption in the year following its September 2023 seed funding, with trial sponsors citing the platform's adaptability to specific study requirements.
Latest developments
In September 2024, Korio announced the completion of a Series A round led by BIP Ventures with participation from existing investors Excelerate Health Ventures and Boston Millennia Partners and other strategic investors, to fund global expansion and its client services and support organization.
▸Full profile — market position, technology, go-to-market, geography, history
Market position
Korio positions itself against legacy IRT providers, which it characterizes as affected by system performance issues, manual processes and employee turnover that lead to trial delays and quality concerns. Its investors describe legacy solutions as struggling with growing study design complexity.
Technology
A compliance-centric IRT/RTSM platform built within a GxP framework, embedding the IRT workflow into the software. Features include reusable client-level study settings applied to subsequent trials, in-platform creation and management of the IRT documentation suite, real-time diagnostics on system availability and performance, audit trail and cross-portfolio data access, and detection of integration disruptions.
Go-to-market
The company states that growth to date has been driven largely by word-of-mouth referrals from existing customers; it also launched publicly at an industry conference (Informa IRT, Boston, October 2022) and uses demo requests via its website.
Clinical trial sponsors and life sciences organizations running randomized clinical trials, along with the trial sites that use the systems.
Geography
Headquartered in Doylestown, Pennsylvania. Series A proceeds were designated for continued global expansion, particularly of the client services and support team.
History
Korio, Inc. announced its compliance-centric IRT platform on September 20, 2022, debuting it at the Informa IRT conference in Boston on October 17-19, 2022, with the solution available to host its first trials that year. The company completed initial seed funding in September 2023 and announced a Series A round in September 2024, following what it described as a surge in customer adoption over the preceding year.
Compiled by commissioned research from 6 cited public sources — announcements, filings, and press listed under research sources below.
Timeline · 4
launches, deals, and filingsKorio announced completion of a Series A round led by BIP Ventures with participation from existing investors Excelerate Health Ventures, Boston Millennia Partners and other strategic investors; proceeds earmarked for global expansion and client services/support.
Korio completed its initial seed funding round, a year before its Series A.
Korio debuted its platform at the Informa IRT conference in Boston, held October 17-19, 2022, with the solution slated to host its first trials that year.
Korio announced an IRT/RTSM solution built within a GxP framework, with reusable client-level study settings, in-platform IRT documentation management and real-time system diagnostics.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
Legal entities · 1
corporate structureIn the news
▸Research sources · 6
primary sources listed
- Korio Secures Series A Funding to Accelerate Growth of Innovative Randomization & Trial Supply Management (RTSM) Platformprnewswire.com · web
6 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Korio do?
- Korio is a clinical technology company offering a randomization and trial supply management (RTSM/IRT) platform for trial sponsors.
- Who are Korio's investors?
- Korio's investors include BIP Ventures, Boston Millennia Partners, Excelerate Health Ventures.
- How much funding has Korio raised?
- Korio has disclosed $12.3M raised across 2 of its 3 known rounds.
- Where is Korio headquartered?
- Korio is headquartered in Doylestown, US.